Shandong Realcan Pharmaceutical Co Ltd (002589) — Capital Reinvestment Ratio

Latest as of June 2025: 2.12x

Shandong Realcan Pharmaceutical Co Ltd (002589) has a Capital Reinvestment Ratio of 2.12x as of June 2025, meaning it reinvests 2% of its operating cash flow (CN¥24.86 Million) in capital expenditures (CN¥52.73 Million). See how much free cash does Shandong Realcan Pharmaceutical Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

2.12x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥24.86 Million
CNY

Capital Expenditures

CN¥52.73 Million
CNY

Data as of

Jun 2025
Most recent filing

Shandong Realcan Pharmaceutical Co Ltd Capital Reinvestment Ratio (2009–2025)

This chart tracks Shandong Realcan Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 9 annual periods.

Annual Capital Reinvestment Ratio for Shandong Realcan Pharmaceutical Co Ltd (2009–2025)

Year-by-year Capital Reinvestment Ratio for Shandong Realcan Pharmaceutical Co Ltd from 2009 to 2025. For live market cap and broader valuation context, see Shandong Realcan Pharmaceutical Co Ltd (002589) market capitalisation.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 1.95x CN¥13.76 Million CN¥26.82 Million ▲ +180.4%
2024 0.70x CN¥160.44 Million CN¥111.53 Million ▼ -80.8%
2023 3.62x CN¥82.47 Million CN¥298.38 Million ▲ +1007.0%
2022 0.33x CN¥523.07 Million CN¥170.96 Million ▼ -68.6%
2021 1.04x CN¥442.95 Million CN¥461.09 Million ▼ -14.5%
2020 1.22x CN¥414.96 Million CN¥505.39 Million ▲ +172.9%
2019 0.45x CN¥2.09 Billion CN¥934.87 Million ▼ -16.5%
2010 0.53x CN¥70.56 Million CN¥37.72 Million ▲ +70.6%
2009 0.31x CN¥61.38 Million CN¥19.23 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow